Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $25.50.

A number of research firms have commented on KURA. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. UBS Group decreased their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Jefferies Financial Group decreased their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, StockNews.com upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, March 7th.

Kura Oncology Trading Down 1.9 %

NASDAQ:KURA opened at $7.14 on Friday. The firm has a market cap of $576.59 million, a P/E ratio of -3.03 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock’s 50 day simple moving average is $7.90 and its 200-day simple moving average is $13.03. Kura Oncology has a 12-month low of $6.79 and a 12-month high of $23.48.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. Equities analysts anticipate that Kura Oncology will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently added to or reduced their stakes in KURA. Barclays PLC increased its stake in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Kura Oncology during the fourth quarter worth about $436,000. Moody Aldrich Partners LLC increased its stake in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after acquiring an additional 42,712 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in Kura Oncology during the fourth quarter worth about $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.